Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Binimetinib

Review the clinical trials studying binimetinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-17 of 17

Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
Status: Active
Location: 13 locations
Binimetinib for the Treatment of Pediatric Progressive or Recurrent Adamantinomatous Craniopharyngioma
Status: Active
Location: 4 locations
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Status: Active
Location: 9 locations
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Status: Active
Location: 7 locations
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Status: Active
Location: 6 locations
Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
Status: Active
Location: 3 locations
Nilotinib in Combination with Dabrafenib and Trametinib or Encorafenib and Binimetinib for the Treatment of BRAF V600 Mutant Metastatic or Unresectable Melanoma
Status: Active
Location: 3 locations
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
Status: Active
Location: 2 locations
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients with Advanced/Metastatic or Unresectable Solid Tumors with RAS Alterations and Triple Negative Breast Cancer
Status: Active
Location: 4 locations
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Status: Active
Location: 2 locations
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Binimetinib plus Belinostat for the Treatment of Metastatic Uveal Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Adjuvant Therapy Based on Pathologic Response after Neoadjuvant Encorafenib and Binimetinib for the Treatment of Stage IIIB-IV Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Targeted Therapy Directed by Genetic Testing in Treating Patients with Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Status: Active
Location: 451 locations